SK Bioscience Co.,Ltd
A biopharma firm developing and manufacturing vaccines and offering CDMO services.
302440 | KO
Overview
Corporate Details
- ISIN(s):
- KR7302440003
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교로 310, 성남시
- Website:
- https://www.skbioscience.com/
- Sector:
- Manufacturing
Description
SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-10-31 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.2 KB | ||
| 2022-10-25 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.3 KB | ||
| 2022-10-19 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.2 KB | ||
| 2022-10-06 00:00 |
투자판단관련주요경영사항(노바백스 코로나19 백신 국내 품목허가 변경 신청(부스터샷 적응증 추가))
|
Korean | 17.8 KB | ||
| 2022-10-04 00:00 |
투자판단관련주요경영사항(COVID-19 백신 GBP510의 이종 부스터샷 네팔 제3상 임상시험계획(IND) 승인)
|
Korean | 11.0 KB | ||
| 2022-09-08 00:00 |
투자판단관련주요경영사항(COVID-19 백신 스카이코비원 세계보건기구(WHO) 긴급사용목록(Emergency Use Listing) 등록서류 …
|
Korean | 7.3 KB | ||
| 2022-09-07 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 22.1 KB | ||
| 2022-09-07 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2022-08-31 00:00 |
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 11.3 KB | ||
| 2022-08-30 00:00 |
투자판단관련주요경영사항(주사형 로타바이러스 백신 임상의 사전 계획된 1단계 무용성 중간평가에 따른 조기 중단)
|
Korean | 7.3 KB | ||
| 2022-08-12 00:00 |
투자판단관련주요경영사항(노바백스 코로나19 백신 국내 품목허가 변경(만 12~17세 청소년 적응증 추가))
|
Korean | 7.9 KB | ||
| 2022-08-12 00:00 |
반기보고서 (2022.06)
|
Korean | 1.7 MB | ||
| 2022-08-08 00:00 |
투자판단관련주요경영사항(COVID-19 백신 GBP510의 이종 부스터샷 네팔 제3상 임상시험계획(IND) 신청)
|
Korean | 10.6 KB | ||
| 2022-08-01 00:00 |
투자판단관련주요경영사항(COVID-19 백신 스카이코비온(GBP510)의 유럽의약품청(EMA) 조건부허가(CMA) 신청)
|
Korean | 11.0 KB | ||
| 2022-07-29 00:00 |
투자판단관련주요경영사항(COVID-19 백신 스카이코비온(GBP510)의 영국 MHRA 조건부허가(CMA) 신청)
|
Korean | 12.2 KB |
Automate Your Workflow. Get a real-time feed of all SK Bioscience Co.,Ltd filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SK Bioscience Co.,Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SK Bioscience Co.,Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
